FDA: More Data Needed to Support Arimoclomol in Niemann-Pick Disease Type C
Neurology Advisor ,
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Orphazyme regarding the New Drug…
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Orphazyme regarding the New Drug…
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Orphazyme regarding the New Drug…
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Orphazyme regarding the New Drug…
Orphazyme (ORPH) slumped on Friday after the Danish biotech firm turned meme stock’s treatment for Niemann-Pick disease type C…